SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts

Initial safety data from Phase 1/2 CYWC628 diabetic foot ulcer trial expected in Q4 2026; interim ef

FBLG

Related stories